Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.

Dammert MA, Brägelmann J, Olsen RR, Böhm S, Monhasery N, Whitney CP, Chalishazar MD, Tumbrink HL, Guthrie MR, Klein S, Ireland AS, Ryan J, Schmitt A, Marx A, Ozretić L, Castiglione R, Lorenz C, Jachimowicz RD, Wolf E, Thomas RK, Poirier JT, Büttner R, Sen T, Byers LA, Reinhardt HC, Letai A, Oliver TG, Sos ML.

Nat Commun. 2019 Aug 2;10(1):3485. doi: 10.1038/s41467-019-11371-x.

2.

Integrative Genomic Characterization Identifies Molecular Subtypes of Lung Carcinoids.

Laddha SV, da Silva EM, Robzyk K, Untch BR, Ke H, Rekhtman N, Poirier JT, Travis WD, Tang LH, Chan CS.

Cancer Res. 2019 Sep 1;79(17):4339-4347. doi: 10.1158/0008-5472.CAN-19-0214. Epub 2019 Jul 12.

PMID:
31300474
3.

Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations.

Devarakonda S, Sankararaman S, Herzog BH, Gold KA, Waqar SN, Ward JP, Raymond VM, Lanman RB, Chaudhuri AA, Owonikoko TK, Li BT, Poirier JT, Rudin CM, Govindan R, Morgensztern D.

Clin Cancer Res. 2019 Jul 12. doi: 10.1158/1078-0432.CCR-19-0879. [Epub ahead of print]

PMID:
31300452
4.

Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.

Laird J, Lok BH, Carney B, Kossatz S, de Stanchina E, Reiner T, Poirier JT, Rudin CM.

J Thorac Oncol. 2019 Jun 11. pii: S1556-0864(19)30453-8. doi: 10.1016/j.jtho.2019.05.032. [Epub ahead of print]

PMID:
31195178
5.

Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 Jul;19(7):415. doi: 10.1038/s41568-019-0164-2.

PMID:
31175338
6.

A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals.

Sharma SK, Lyashchenko SK, Park HA, Pillarsetty N, Roux Y, Wu J, Poty S, Tully KM, Poirier JT, Lewis JS.

Nucl Med Biol. 2019 Apr;71:32-38. doi: 10.1016/j.nucmedbio.2019.04.005. Epub 2019 May 3.

PMID:
31128476
7.

Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data.

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF.

Nat Rev Cancer. 2019 May;19(5):289-297. doi: 10.1038/s41568-019-0133-9. Review. Erratum in: Nat Rev Cancer. 2019 Jun 7;:.

PMID:
30926931
8.

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R, Schoenfeld AJ, Plodkowski AJ, Poirier JT, Rudin CM, Kris MG, Rosen NX, Yu HA, Riely GJ, Arcila ME, Somwar R, Ladanyi M.

J Thorac Oncol. 2019 May;14(5):802-815. doi: 10.1016/j.jtho.2018.12.038. Epub 2019 Mar 1.

PMID:
30831205
9.

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition.

Augert A, Eastwood E, Ibrahim AH, Wu N, Grunblatt E, Basom R, Liggitt D, Eaton KD, Martins R, Poirier JT, Rudin CM, Milletti F, Cheng WY, Mack F, MacPherson D.

Sci Signal. 2019 Feb 5;12(567). pii: eaau2922. doi: 10.1126/scisignal.aau2922.

PMID:
30723171
10.

ONECUT2 is a driver of neuroendocrine prostate cancer.

Guo H, Ci X, Ahmed M, Hua JT, Soares F, Lin D, Puca L, Vosoughi A, Xue H, Li E, Su P, Chen S, Nguyen T, Liang Y, Zhang Y, Xu X, Xu J, Sheahan AV, Ba-Alawi W, Zhang S, Mahamud O, Vellanki RN, Gleave M, Bristow RG, Haibe-Kains B, Poirier JT, Rudin CM, Tsao MS, Wouters BG, Fazli L, Feng FY, Ellis L, van der Kwast T, Berlin A, Koritzinsky M, Boutros PC, Zoubeidi A, Beltran H, Wang Y, He HH.

Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.

11.

NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination.

Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, Baslan T, Tian S, Chen HA, Romesser PB, Poirier JT, Rudin CM, de Stanchina E, Manchado E, Sherr CJ, Lowe SW.

Science. 2018 Dec 21;362(6421):1416-1422. doi: 10.1126/science.aas9090.

12.

Peptide-based PET quantifies target engagement of PD-L1 therapeutics.

Kumar D, Lisok A, Dahmane E, McCoy M, Shelake S, Chatterjee S, Allaj V, Sysa-Shah P, Wharram B, Lesniak WG, Tully E, Gabrielson E, Jaffee EM, Poirier JT, Rudin CM, Gobburu JV, Pomper MG, Nimmagadda S.

J Clin Invest. 2019 Feb 1;129(2):616-630. doi: 10.1172/JCI122216. Epub 2019 Jan 7.

13.

ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching.

Cifani P, Dhabaria A, Chen Z, Yoshimi A, Kawaler E, Abdel-Wahab O, Poirier JT, Kentsis A.

J Proteome Res. 2018 Nov 2;17(11):3681-3692. doi: 10.1021/acs.jproteome.8b00295. Epub 2018 Oct 19.

14.

Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.

Laird JH, Lok BH, Ma J, Bell A, de Stanchina E, Poirier JT, Rudin CM.

Clin Cancer Res. 2018 Oct 15;24(20):5143-5152. doi: 10.1158/1078-0432.CCR-18-0401. Epub 2018 Jun 26.

PMID:
29945991
15.

Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.

Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, Dilling TR, Abdel-Atti D, Zeglis BM, Poirier JT, Lewis JS.

Cancer Res. 2018 Apr 1;78(7):1820-1832. doi: 10.1158/0008-5472.CAN-17-1958. Epub 2018 Jan 23.

16.

Target engagement imaging of PARP inhibitors in small-cell lung cancer.

Carney B, Kossatz S, Lok BH, Schneeberger V, Gangangari KK, Pillarsetty NVK, Weber WA, Rudin CM, Poirier JT, Reiner T.

Nat Commun. 2018 Jan 12;9(1):176. doi: 10.1038/s41467-017-02096-w.

17.

CRISPR Libraries and Screening.

Poirier JT.

Prog Mol Biol Transl Sci. 2017;152:69-82. doi: 10.1016/bs.pmbts.2017.10.002. Epub 2017 Nov 6.

PMID:
29150005
18.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

19.

Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus.

Miles LA, Burga LN, Gardner EE, Bostina M, Poirier JT, Rudin CM.

J Clin Invest. 2017 Aug 1;127(8):2957-2967. doi: 10.1172/JCI93472. Epub 2017 Jun 26.

20.

Unravelling the biology of SCLC: implications for therapy.

Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM.

Nat Rev Clin Oncol. 2017 Sep;14(9):549-561. doi: 10.1038/nrclinonc.2017.71. Epub 2017 May 23. Review.

21.

Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.

Sharma SK, Pourat J, Abdel-Atti D, Carlin SD, Piersigilli A, Bankovich AJ, Gardner EE, Hamdy O, Isse K, Bheddah S, Sandoval J, Cunanan KM, Johansen EB, Allaj V, Sisodiya V, Liu D, Zeglis BM, Rudin CM, Dylla SJ, Poirier JT, Lewis JS.

Cancer Res. 2017 Jul 15;77(14):3931-3941. doi: 10.1158/0008-5472.CAN-17-0299. Epub 2017 May 9.

22.

Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses NF2 Loss-Driven Tumorigenesis.

Cooper J, Xu Q, Zhou L, Pavlovic M, Ojeda V, Moulick K, de Stanchina E, Poirier JT, Zauderer M, Rudin CM, Karajannis MA, Hanemann CO, Giancotti FG.

Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.

23.

Histone Code Aberrancies in Small Cell Lung Cancer.

Gardner EE, Poirier JT, Rudin CM.

J Thorac Oncol. 2017 Apr;12(4):599-601. doi: 10.1016/j.jtho.2017.02.008. No abstract available.

24.

Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.

Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT.

Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006.

25.

Small-cell lung cancer in 2016: Shining light on novel targets and therapies.

Rudin CM, Poirier JT.

Nat Rev Clin Oncol. 2017 Feb;14(2):75-76. doi: 10.1038/nrclinonc.2016.203. Epub 2016 Dec 13. No abstract available.

PMID:
27958293
26.

Quantitation of Murine Stroma and Selective Purification of the Human Tumor Component of Patient-Derived Xenografts for Genomic Analysis.

Schneeberger VE, Allaj V, Gardner EE, Poirier JT, Rudin CM.

PLoS One. 2016 Sep 9;11(9):e0160587. doi: 10.1371/journal.pone.0160587. eCollection 2016.

27.

PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.

Lok BH, Gardner EE, Schneeberger VE, Ni A, Desmeules P, Rekhtman N, de Stanchina E, Teicher BA, Riaz N, Powell SN, Poirier JT, Rudin CM.

Clin Cancer Res. 2017 Jan 15;23(2):523-535. doi: 10.1158/1078-0432.CCR-16-1040. Epub 2016 Jul 20.

28.

P-selectin is a nanotherapeutic delivery target in the tumor microenvironment.

Shamay Y, Elkabets M, Li H, Shah J, Brook S, Wang F, Adler K, Baut E, Scaltriti M, Jena PV, Gardner EE, Poirier JT, Rudin CM, Baselga J, Haimovitz-Friedman A, Heller DA.

Sci Transl Med. 2016 Jun 29;8(345):345ra87. doi: 10.1126/scitranslmed.aaf7374.

29.

A combinatorial strategy for treating KRAS-mutant lung cancer.

Manchado E, Weissmueller S, Morris JP 4th, Chen CC, Wullenkord R, Lujambio A, de Stanchina E, Poirier JT, Gainor JF, Corcoran RB, Engelman JA, Rudin CM, Rosen N, Lowe SW.

Nature. 2016 Jun 30;534(7609):647-51. Epub 2016 Jun 22.

30.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

31.

Design, execution, and analysis of pooled in vitro CRISPR/Cas9 screens.

Miles LA, Garippa RJ, Poirier JT.

FEBS J. 2016 Sep;283(17):3170-80. doi: 10.1111/febs.13770. Epub 2016 Jun 16. Review.

32.

Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets.

Rekhtman N, Pietanza MC, Hellmann MD, Naidoo J, Arora A, Won H, Halpenny DF, Wang H, Tian SK, Litvak AM, Paik PK, Drilon AE, Socci N, Poirier JT, Shen R, Berger MF, Moreira AL, Travis WD, Rudin CM, Ladanyi M.

Clin Cancer Res. 2016 Jul 15;22(14):3618-29. doi: 10.1158/1078-0432.CCR-15-2946. Epub 2016 Mar 9.

33.

Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts.

Behnam Azad B, Lisok A, Chatterjee S, Poirier JT, Pullambhatla M, Luker GD, Pomper MG, Nimmagadda S.

J Nucl Med. 2016 Jun;57(6):981-8. doi: 10.2967/jnumed.115.167932. Epub 2016 Feb 23.

34.

Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?

Bunn PA Jr, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR.

J Thorac Oncol. 2016 Apr;11(4):453-74. doi: 10.1016/j.jtho.2016.01.012. Epub 2016 Jan 30. Review. No abstract available.

35.

A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, Desai R, Escarpe PA, Hampl J, Laysang A, Liu D, Lopez-Molina J, Milton M, Park A, Pysz MA, Shao H, Slingerland B, Torgov M, Williams SA, Foord O, Howard P, Jassem J, Badzio A, Czapiewski P, Harpole DH, Dowlati A, Massion PP, Travis WD, Pietanza MC, Poirier JT, Rudin CM, Stull RA, Dylla SJ.

Sci Transl Med. 2015 Aug 26;7(302):302ra136. doi: 10.1126/scitranslmed.aac9459.

36.

Correction: Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for use in Peptide-Prodrug Therapy.

Miles LA, Brennen WN, Rudin CM, Poirier JT.

PLoS One. 2015 Aug 19;10(8):e0136480. doi: 10.1371/journal.pone.0136480. eCollection 2015. No abstract available.

37.

Seneca Valley Virus 3Cpro Substrate Optimization Yields Efficient Substrates for Use in Peptide-Prodrug Therapy.

Miles LA, Brennen WN, Rudin CM, Poirier JT.

PLoS One. 2015 Jun 12;10(6):e0129103. doi: 10.1371/journal.pone.0129103. eCollection 2015. Erratum in: PLoS One. 2015;10(8):e0136480.

38.

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.

Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, Miyoshi N, VanderLaan PA, Costa DB, Jänne PA, Borger DR, Ramaswamy S, Shioda T, Iafrate AJ, Getz G, Rudin CM, Mino-Kenudson M, Engelman JA.

Nat Commun. 2015 Mar 11;6:6377. doi: 10.1038/ncomms7377.

39.

DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.

Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM.

Oncogene. 2015 Nov 26;34(48):5869-78. doi: 10.1038/onc.2015.38. Epub 2015 Mar 9.

40.

Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer.

Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM.

Oncotarget. 2015 Jan 1;6(1):56-70.

41.

Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.

Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM.

Pediatr Blood Cancer. 2015 May;62(5):743-50. doi: 10.1002/pbc.25269. Epub 2014 Oct 12.

42.

RET mutations in neuroendocrine tumors: including small-cell lung cancer.

Rudin CM, Drilon A, Poirier JT.

J Thorac Oncol. 2014 Sep;9(9):1240-2. doi: 10.1097/JTO.0000000000000301. No abstract available.

43.

Rapamycin rescues ABT-737 efficacy in small cell lung cancer.

Gardner EE, Connis N, Poirier JT, Cope L, Dobromilskaya I, Gallia GL, Rudin CM, Hann CL.

Cancer Res. 2014 May 15;74(10):2846-56. doi: 10.1158/0008-5472.CAN-13-3460. Epub 2014 Mar 10.

44.

MYC, MAX, and small cell lung cancer.

Rudin CM, Poirier JT.

Cancer Discov. 2014 Mar;4(3):273-4. doi: 10.1158/2159-8290.CD-14-0069.

45.

Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer.

Poirier JT, Dobromilskaya I, Moriarty WF, Peacock CD, Hann CL, Rudin CM.

J Natl Cancer Inst. 2013 Jul 17;105(14):1059-65. doi: 10.1093/jnci/djt130. Epub 2013 Jun 5.

46.

Characterization of a full-length infectious cDNA clone and a GFP reporter derivative of the oncolytic picornavirus SVV-001.

Poirier JT, Reddy PS, Idamakanti N, Li SS, Stump KL, Burroughs KD, Hallenbeck PL, Rudin CM.

J Gen Virol. 2012 Dec;93(Pt 12):2606-13. doi: 10.1099/vir.0.046011-0. Epub 2012 Sep 12.

PMID:
22971818
47.

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer.

Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, Bergbower EA, Guan Y, Shin J, Guillory J, Rivers CS, Foo CK, Bhatt D, Stinson J, Gnad F, Haverty PM, Gentleman R, Chaudhuri S, Janakiraman V, Jaiswal BS, Parikh C, Yuan W, Zhang Z, Koeppen H, Wu TD, Stern HM, Yauch RL, Huffman KE, Paskulin DD, Illei PB, Varella-Garcia M, Gazdar AF, de Sauvage FJ, Bourgon R, Minna JD, Brock MV, Seshagiri S.

Nat Genet. 2012 Oct;44(10):1111-6. doi: 10.1038/ng.2405. Epub 2012 Sep 2.

48.

Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.

Rudin CM, Poirier JT, Senzer NN, Stephenson J Jr, Loesch D, Burroughs KD, Reddy PS, Hann CL, Hallenbeck PL.

Clin Cancer Res. 2011 Feb 15;17(4):888-95. doi: 10.1158/1078-0432.CCR-10-1706. Epub 2011 Feb 8.

49.

Supplemental Content

Loading ...
Support Center